Pluristem Therapeutics Inc (PSTI)

[EichKing]

D....I too think this is positive news...but as usual PPS reacts poorly. If you consider $1.25 good, well that speaks volumes. What we need is some real efficacy validation and some forecasted revenue with firm dates. True metrics are all that will move this stock up in a material manner. Expecting PPS to move on "approved trials" has not only shown to be nothing but cash burn, these PR's have been detrimental to PPS. BTW, the fact IU will pay for cells is good, so there is some revenue there and the funding will help limit cash burn....but our $5 mm per quarter burn will remain the same or go a bit higher.